Clinical Trial

Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma

Name: Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma — clinical trial record (NCT06933394)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of the combination therapy involving arsenic trioxide, MAPK inhibitors, and chemotherapy for stage 4/M neuroblastoma.

Trial Details

NCT Number	NCT06933394
Lead Sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions	Neuroblastoma
Enrollment	92 participants
Start Date	2025-05-01
Primary Completion	2031-05-01 (estimated)
Study Completion	2031-05-01 (estimated)
Updated on ClinicalTrials.gov	2025-04-18